Maximizing Returns: A Strategy for 10% Yield with BSX Stock
Money

Maximizing Returns: A Strategy for 10% Yield with BSX Stock

authorBy Mr. Money Mustache
DateJul 07, 2026
Read Time2 min

Investors are consistently seeking methods to generate substantial returns while mitigating risk. One such strategy involves leveraging options contracts to create an income stream and establish a favorable entry point for stocks experiencing volatility.

For instance, consider Boston Scientific (BSX), a medical device manufacturer that has recently faced a significant downturn, with its stock price dropping by approximately 59% from its 52-week peak. This decline presents a unique opportunity for investors to utilize a cash-secured put option strategy. By selling a put option on BSX with an expiration date of June 17, 2027, and a strike price of $30, an investor can collect an immediate premium of roughly $170 per contract. This translates to an annualized yield of about 6.0% on the $3,000 cash set aside to secure the trade. Furthermore, by parking this reserved cash in a high-yield money market or savings account earning around 4.0%, the total annualized yield can reach approximately 10.0%. If BSX's price remains above $30 until expiration, the put option expires worthless, and the investor retains the premium, effectively earning a solid return without owning the stock. Conversely, if the stock falls below $30, the investor is obligated to purchase the shares at $30, but the collected premium reduces the effective cost per share to about $28.30, representing a substantial discount of approximately 37% from its current trading price.

This strategy addresses the inherent risks associated with a stock like BSX, which recently cut its full-year guidance due to underperforming segments such as WATCHMAN heart devices, electrophysiology, and urology. However, the company also demonstrates resilience, with other divisions like Neuromodulation and Interventional Oncology showing robust organic sales growth of 15% in the first quarter, and adjusted earnings growth projected at 9% to 11% for the year, indicating effective cost management. The appeal of this options strategy lies in its ability to generate income while providing a built-in margin of safety. It allows investors to capitalize on potential future recovery, or acquire shares at a deep discount if challenges persist. This approach, while effective for individual stock opportunities, is best integrated within a diversified portfolio, such as the Trefis High Quality (HQ) Portfolio, which combines active, researched ideas with a core of fundamentally strong businesses, to ensure a balanced investment strategy.

Embracing a well-considered investment strategy, like the one outlined, empowers individuals to navigate market fluctuations with confidence. By diligently researching opportunities and employing disciplined approaches, investors can not only achieve their financial objectives but also contribute to a more stable and prosperous economic landscape. Such proactive engagement fosters financial literacy and resilience, paving the way for sustained growth and positive impact.

More Articles
Money
Australia-Style Retirement Accounts: A Game Changer for American Workers?
Former President Trump's proposal for Australia-style employer-funded retirement accounts could significantly impact American workers, especially those relying solely on Social Security. This system, where employers contribute a percentage of wages to individual, market-invested accounts, offers a supplement to existing retirement plans, providing a new avenue for wealth accumulation and addressing the shortcomings of Social Security's current funding model.
By Dave RamseyJul 07, 2026
Money
CoreWeave Inc. (CRWV) Experiences Significant Stock Drop Following Jim Cramer's Endorsement
Despite Jim Cramer's positive outlook, CoreWeave Inc. (CRWV) has seen its stock price fall by nearly 20% since his January remarks. The company's recent earnings report, though showing increased revenue, revealed higher-than-expected losses and capital expenditures, further impacted by Meta's announcement to sell excess compute capacity.
By Natalie PaceJul 07, 2026
Money
AppLovin (APP) Stock Performance After Jim Cramer's Recommendation
This article examines the stock performance of AppLovin Corporation (APP) following Jim Cramer's positive recommendation. Despite Cramer's initial comfort in recommending the stock due to its strong growth and profitability in the advertising software sector, the company's shares have experienced significant fluctuations, including a recent downturn. Factors such as Google's Project Genie and competition from Meta are explored as potential influences on its market behavior.
By Dave RamseyJul 07, 2026
Money
DuPont de Nemours Attracts Investor Confidence with Strong Performance and Analyst Upgrades
DuPont de Nemours (NYSE:DD) has demonstrated robust growth, with its shares climbing significantly over the past year and year-to-date. Esteemed financial institutions like RBC Capital and Citi have issued favorable outlooks and raised price targets, highlighting the company's strong performance, particularly its electronics division spinoff. The chemical giant's recent first-quarter earnings exceeded analyst expectations, further solidifying its position as a compelling investment opportunity.
By JL CollinsJul 07, 2026
Money
DENTSPLY SIRONA Inc. (XRAY): Stock Performance Post-Cramer's Remarks
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has experienced fluctuating stock performance following Jim Cramer's commentary. The dental products manufacturer saw its shares initially rise by 15.5% after its Q4 earnings beat revenue estimates, despite an overall 26.9% decline over the past year. Cramer expressed confidence in the stock's value, suggesting it could be a worthwhile long-term investment.
By Scott PapeJul 07, 2026